QP-Prostate® Receives Health Canada Licence, Expanding Quibim’s Reach to Canada 

  • QP-Prostate® has received Medical Device Licence from Health Canada, opening the Canadian market to Quibim’s AI-powered prostate MRI analysis tool. 
  • Canada joins the EU, the US, the UK, Switzerland, Chile, Mexico, Argentina, Brazil and Australia as markets where QP-Prostate® is cleared for clinical use. 

 

10 June 2026, Valencia – Quibim has received the QP-Prostate® Licence from Health Canada, its AI-powered solution for prostate MRI analysis. The decision clears QP- Prostate® v2.4 for use across Canada, where prostate cancer is the most commonly diagnosed cancer among men. 

QP-Prostate® uses artificial intelligence to analyze prostate MRI scans, giving clinicians quantitative imaging data to support the detection and characterization of prostate cancer. The tool works within existing clinical workflows without requiring changes to imaging protocols. 

QP-Prostate® already holds CE marking for the European Union, a UKCA mark for the United Kingdom, FDA clearance for the United States, TGA approval for Australia, and clearances for Switzerland, Chile, Mexico, Argentina and Brazil, meaning it is cleared for use by clinicians in all those markets. 

Nathan Clark, Chief Commercial Officer at Quibim, said: “Receiving this Health Canada Licence means QP-Prostate® is now cleared in most of the countries around the globe. With each new market, more clinicians and patients gain access to AI-powered prostate MRI analysis — and prostate cancer is one of the most common diagnoses facing men in Canada. We look forward to working with the Canadian healthcare community.” 

About Quibim 

Quibim is a Spanish company that designs pioneering tools to leverage imaging data and improve patient outcomes. With offices in New York (USA), Cambridge (UK), Valencia, Madrid, and Barcelona (Spain), the company was founded with the ambition of turning imaging into a catalyst for precision medicine. Quibim leads imaging biomarker research in the life sciences, developing advanced algorithms that transform imaging data into actionable predictions in oncology, immunology, and neurology. The company uses MRI, CT, and PET to create regulatory-approved medical devices seamlessly integrated into clinical workflows worldwide. More information at quibim.ai. 

Quibim Website
Powered by  GDPR Cookie Compliance
Privacy Overview

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mainly used to make the site work as you expect it to. The information does not directly identify you but can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. However, blocking some types of cookies may impact your experience of the site. You can find more information, including a detailed cookie explanation, on our Cookie Policy.